JNJ Dec 2020 135.000 put

OPR - OPR Delayed price. Currency in USD
4.1500
-0.3500 (-7.78%)
As of 11:02AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close4.5000
Open4.2500
Bid4.0000
Ask4.2000
Strike135.00
Expiry date2020-12-18
Day's range4.1500 - 4.2500
Contract rangeN/A
Volume4
Open interest958
  • 5 Top Dividend Kings to Buy and Hold Forever
    Motley Fool

    5 Top Dividend Kings to Buy and Hold Forever

    Most income investors are likely familiar with the Dividend Aristocrats -- elite members of the S&P 500 index that have raised their payouts annually for at least 25 straight years. But there's an even more rarefied rank (though one not restricted to S&P 500 members).

  • Bloomberg

    Big Pharma Shouldn’t Be Too Greedy

    (Bloomberg Opinion) -- Intellectual property is a convenient fiction. It is a right enforced by state power and international agreements, one that’s even more fragile than other forms of property rights since it’s not tangible. We choose to believe this fiction because we also believe that intellectual property adds to general welfare. It permits innovation and growth, and supports writers, artists, inventors — and pharmaceutical companies.But crises upend beliefs and we are in a crisis at the moment. We should all hope the tradition of treating intellectual property as a real thing survives the pandemic. That hope must be especially keen among the companies most at risk if the myth breaks down: the pharma industry.Nothing is more likely to test this consensus than hints of profiteering off the war against Covid-19. A Financial Times report that the U.S.-based company Moderna Inc. has sought to price its vaccine candidate around $50-$60 per course, for example, has shaken public health establishments across the world. The story also suggested that while Moderna might offer developing countries a lower price, rich countries would get privileged access to the vaccine.Let me tell you the consequences if that happens and Moderna’s vaccine performs better than its cheaper competitors: The patent on the vaccine will be widely ignored. The consensus on intellectual property, painstakingly built up over time and spread worldwide over the past two decades, will be busted.I don’t want to single out Moderna here. It doesn’t have a single successful commercial drug, nor any other Phase 3 candidates; its need to make money off this vaccine is arguably acute. Larger drug companies are different. Yet Pfizer Inc.’s CEO recently said that calls for companies not to consider making a profit on their Covid-19 vaccines were “fanatic and radical.” (AstraZeneca PLC and Johnson & Johnson have promised a not-for-profit effort on their Covid-19 vaccines, so Pfizer clearly has an odd definition of “fanatic and radical.”)If a vaccine proves too expensive or difficult to obtain, those who seek exorbitant profits off of it will be scrutinized far more closely than bankers were after the 2008 crash. Actions like those that have already allowed insiders to pocket $80 million will provoke public revulsion, even if those trades were pre-scheduled. Calls to regulate sectors that take for granted intellectual property protections will grow exponentially. Those demands won’t be fanatical or radical, but mainstream.It will be hard enough to preserve the myth of intellectual property within rich countries. Once international capital flows are involved, it’ll be impossible. Cash-strapped governments around the world are not going to pay tens of billions for vaccines needed to save the lives of their citizens. Any attempts to collect using the traditional trading and legal architecture will be ignored — and will indeed lead to those institutions being seen as discredited or even immoral.There is a lesson here that goes beyond the pandemic. If we are not sufficiently careful over the next decade, one likely economic future consists of tech lords, data czars and algorithm owners sitting in the U.S. or in China soaking up rents and payments from consumers in the rest of the world. That is simply unsustainable. Asian, African and even European governments will step in and prevent those streams of payments from being made. Global intellectual property requires the consent and enforcement of every state, not just one government. That consent will not be given if the capital flows involved appear to be one-way and permanent.A world without global intellectual property would be one of constant electronic warfare. State-backed hacking, such as China apparently tried with Moderna this week, would be a constant threat. Nor would companies enjoy a comfortable relationship with their own governments, who would see them less as engines of growth and more as storehouses of national wealth and security. The days before copyright were tough. When the Murano glassmakers’ industrial processes were considered state secrets in the Republic of Venice, the doges would kill any artisan who left the island.That isn’t a world we want to live in. It’s up to pharma companies and rich-country governments to ensure that we’re not forced to do so. The World Health Organization has asked those with relevant intellectual property to sign up to the Covid-19 Technology Access Pool, which will make vaccines broadly available across the world. Too few have.Perhaps, as some pharma companies have done, IP holders can make it clear they will only seek to profit from their vaccines once the pandemic is over. A little patience would serve them — and the world — well in the long run.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Mihir Sharma is a Bloomberg Opinion columnist. He was a columnist for the Indian Express and the Business Standard, and he is the author of “Restart: The Last Chance for the Indian Economy.”For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • 2 Stocks to Bankroll Your Retirement
    Motley Fool

    2 Stocks to Bankroll Your Retirement

    As more pharmaceutical companies jump into the race to develop a coronavirus vaccine, possible winners and losers have already begun to emerge. Shares of Johnson & Johnson (NYSE: JNJ) took a nosedive in March with the rest of the market, but have rebounded back near where they were at the beginning of January. Johnson & Johnson reported more than $82 billion in sales in 2019, representing 2.8% earnings growth on an operational basis.

  • 2 Dividend Stocks You Can Safely Hold for Decades
    Motley Fool

    2 Dividend Stocks You Can Safely Hold for Decades

    Johnson & Johnson (NYSE: JNJ) is a top healthcare company known by consumers all around the world for its various products and drugs. Versatility is important during these difficult times, and with three strong business segments -- consumer health, pharmaceuticals, and medical devices -- Johnson & Johnson is a more stable long-term investment thanks to its diversification. Johnson & Johnson has begun human trials, and if the vaccine proves to be effective, the company could have as many as 900 million doses of it available by April 2021.

  • Bloomberg

    Vaccine Confronts Humanity With Next Moral Test

    (Bloomberg Opinion) -- The coronavirus pandemic has stress-tested the world. Beyond challenging human fortitude, national health services and international rivalries, it has forced a series of moral choices. Many have provoked impassioned disagreement — over whether governments can force businesses and schools to close, over sacrifices for the sake of the elderly and, most bitterly and surprisingly, over whether being asked to wear a simple face mask infringes individual liberty.The toughest moral test lies ahead. The biomedical industry and research facilities around the world are progressing toward creating a vaccine that would offer the best chance to end the pandemic and return life to normal. But the moral dilemmas provoked by the development and distribution of a vaccine will drive ever deeper debates.The issues strike at profound divisions between schools of ethics. The newly published "Ethics and Pandemics," an anthology edited by philosophy professor Meredith Schwartz of Ryerson University in Toronto, presents contrasting views of academics, doctors and commentators along with a series of impossibly difficult case studies. The scientific, economic and political choices involve moral issues that have divided ethicists for centuries:How to Develop It?The U.S government says the Covid-19 vaccine will be developed “at warp speed.” But vaccines take years to develop, for good reasons, and none of the benefits can be realized if they are released before they are safe. A failed Covid-19 vaccine could even compromise confidence in other vaccinations, threatening a return of measles, polio and other plagues.Testing shortcuts are available but fraught. The first rule of deciding when they’re justified, explains Arthur Caplan, the head of bioethics at the NYU Langone hospital system in New York, is that risks can be balanced against the prospect of better data. Thus, skipping animal testing may pass muster since the data from testing humans is better.That leads to the issue that divides teams at Moderna Inc. in Boston and at Oxford University in England who are working on the two most promising attempts to find a vaccine. How much risk of harming humans can they justifiably take? The best way to accelerate the process could fall afoul of the long-established obligations of medical ethics, from the Hippocratic oath to “do no harm.”That pledge is as old as ancient Greece, it aligns with Christian teaching, and with the powerful school of rights-based philosophy identified with the 18th-century German philosopher Immanuel Kant, which holds that people should never treat humanity as a means to an end. Whatever the ultimate positive consequences, Kantians argue, there is no right to harm anyone. Virtuous ends do not justify unethical means.In "human challenge trials," which have been used to test cholera and dengue vaccines, volunteers are injected with a vaccine and then deliberately infected with the germ that researchers are hoping to neutralize. The subjects are tightly monitored, and results are available within weeks. Researchers at Oxford are developing strains of the coronavirus in preparation for such a trial, as are the National Institutes of Health in the U.S. Such a study will require 150 volunteers at the most.Moderna opted against human challenge trials, and instead started a conventional trial with 30,000 test subjects in July. Volunteers are given either the vaccine or a placebo, and then go about their daily lives as the pandemic rages. Moderna hopes to have scientifically reliable results by the end of the year.Tal Zaks, Moderna’s chief medical officer, said he expects this approach to reveal how the vaccine behaves with different groups of people and in different regions. By testing in the real world, he said, results can be superior to the outcome of challenge tests, which are held in laboratory conditions.But the conventional approach is slower, and leaves much to chance. Oxford’s attempt to hold such a study in London and Oxford earlier this year came just as the epidemic was beginning to decline in the U.K., making it hard to draw firm conclusions. A rival research team at Imperial College, London, has the same problem and is looking to hold a trial in another country.Further, doctors are morally obliged to tell volunteers how to avoid getting infected. They cannot tell them to go maskless, or to seek out crowded spaces, even though from a narrowly scientific point of view this would improve their test results. It’s also impossible to monitor so many volunteers closely enough to determine if they are reporting their experiences inaccurately and skewing the results.Rutgers University bioethicist Nir Eyal says that coronavirus challenge testing in the U.S could simultaneously “maximize utility and respect rights.” Researchers would use only “informed, willing, low-risk volunteers” from a population that is already in high-risk areas, he said.Volunteers are abundant. An advocacy group called 1 Day Sooner has found 32,000 volunteers in 140 countries, all between the ages of 20 and 30, (old enough to consent but much less exposed to serious harm from Covid-19 than their elders) with no relevant underlying medical conditions. Strongly believing in effective altruism, Josh Morrison, who heads 1 Day Sooner, voluntarily donated one of his kidneys to a stranger, as did others helping with the campaign.But Kantian objections are serious. Michael Rosenblatt, a Harvard Medical School professor and former chief medical officer of Merck Inc., objects that human challenge studies should only be contemplated when some lifesaving treatment, such as an antiviral medicine, is available for a candidate who gets sick. There is no such cure for Covid-19. Then there is the problem of the unknown. Vaccines must pass muster with libertarians, descended from figures such as the enlightenment philosopher John Locke and the founding fathers of the U.S., who build morality around individual freedom. To counter libertarian objections, researchers must obtain “informed consent.” Rosenblatt argues that when it comes to Covid-19, “It’s pretty hard to have informed consent when we barely know anything about this yet.” There are fears that the virus can cause lasting damage even in twentysomethings, for example, but little clear evidence. Can volunteers really consent to expose themselves to such poorly understood risks?Finally, there is the appalling possibility of a volunteer dying. In 1999, this happened to Jesse Gelsinger, a healthy 18-year-old with a rare metabolic genetic disorder who volunteered for a conventional safety trial (not a challenge trial) of a virus-based gene therapy. His death was both a personal tragedy and a scientific disaster that “set the field of gene therapy back by at least two decades,” Rosenblatt said. “That hiatus deprived a generation of patients with genetic disorders of treatments.”Morrison, of 1 Day Sooner, defends the right to volunteer for testing. Estimates at present are that the risk of death from Covid-19 for people in their 20s with no pre-existing conditions is under one in 10,000 — less than the risk of dying in childbirth while soldiers (whether volunteer or conscripted) face a far higher chance of dying on the battlefield.How to Pay for It?“A vaccine is meaningless if people are unable to afford it,” said John Young, the chief management officer of Pfizer Inc. Nobody asserts that drug companies should be able to charge whatever the market can bear for a Covid-19 vaccine. But private companies like Pfizer have a responsibility to shareholders. Moreover, anyone who develops a successful coronavirus vaccine will have performed an immense service to humanity and will deserve to be rewarded. And so Pfizer defends its right to make a profit.Pfizer has a $2 billion deal with the U.S. government to supply as many as 600 million doses of the vaccine it is developing. Many of its competitors are in collaborations with public universities, or receive state funding. That raises an intensely ideological issue: Should a private company be free to set prices for a public good developed with government aid?“We have to make a profit out of the first product,” Moderna chief executive Stephane Bancel told Yahoo Finance. “We have invested $2 billion of our shareholder capital since we started the company. We need to get a return.” But Moderna has also received some $955 million in government funding to finance its big test. According to the Financial Times, Moderna is planning to price its vaccine at $25-$30 per dose, significantly above the $19.50 at which Pfizer is selling each of 100 million doses to the U.S..Meanwhile, AstraZeneca PLC says it will sell the vaccine it is developing with Oxford to European governments at no profit, while Johnson & Johnson says it will sell its vaccine at a “not-for-profit price” for emergency use. The issue is already very political. Five pharma industry leaders have had to testify on their pricing plans before a committee of the U.S. House of Representatives, and Democratic-sponsored bills are in Congress to stop price gouging. They have some Republican support. Representative Lloyd Doggett, a Texas Democrat who is sponsoring one such bill, told Politico that “a drug company’s claim that it’s providing a vaccine at cost should be viewed with the same skepticism as that by a used car salesperson.” Once governments have bought the vaccine, should they require patients to pay for their own shots? Most people with money would happily pay much more than $30 to free themselves from the coronavirus. But in the many developed countries with nationalized health systems, the question doesn’t arise: taxpayers pay, and the vaccine is free for patients.The U.S., however, has a political issue on its hands. Senator Patty Murray, a Washington Democrat, now backs a bill to ensure that every American has a right to a free vaccine. Meanwhile, the deal with Pfizer will result in free immunizations. Having established the principle of taxpayer-paid vaccines, it could be hard to retreat.These are issues decided within countries. When it comes to international cooperation, poorer countries complain about “vaccine nationalism.” In the U.K., Prime Minister Boris Johnson pulled out of the EU’s so-called Inclusive Vaccines Alliance in a move attacked for playing to his Brexit-friendly political base.Wealthy countries have little incentive to collaborate with poor ones. Costa Rica led an effort with the World Health Organization to set up a new “Covid-19 Technology Access Pool” that would share research and then coordinate production – and also share the vaccine once it was ready.But the list of countries that responded is telling. The U.S., China, Canada and Japan are all absent, while the only European countries to sign up have been Belgium, Luxembourg, the Netherlands and Norway. A group of much smaller developing nations has been left to build a collaboration — even though the virus knows no boundaries, and it is in all countries’ interest to stamp it out everywhere.Meanwhile, rich countries are prospectively buying up vaccines before they have even been cleared for use. The U.S.-Pfizer vaccine deal, and a similar deal with Glaxo PLC and Sanofi AG, uses American buying power to avoid excessive prices. Britain has done four separate deals with providers for 250 million doses.What about the poorer countries who may have to pay more for the vaccine? For now, attempts at “vaccine justice” have been left to philanthropies such as the Gates Foundation’s Vaccine Network.How to Ration It?The pharmaceutical industry cannot produce enough vaccine for the entire global population of almost 8 billion all at once. Therefore, rationing is inevitable. Some people will have to wait. Who gets to make these decisions, and by what criteria?Within the U.S., various medical bodies and government agencies claim authority to draw up the guidelines. No one seems empowered to adjudicate.“The principle is to protect those most likely to be harmed,” said Caplan of NYU Langone. That leads to one point of clarity: Medical workers go first. They’re obviously at risk, and have a duty to put themselves in harm’s way.But after this, following his criterion leads to prioritizing some of the least privileged in society – not because they are underprivileged and deserve help, but because they are most at risk.Statistically, prisoners follow doctors and nurses on the list of people most likely to be harmed. As prisons are Covid-19 incubators, Caplan suggests that vaccinating inmates would limit the disease’s spread.Within the U.S., Native-American communities are grievously affected, and therefore have a case for priority. The same is true of some other ethnic minorities, largely because they tend to live in crowded communities, and because higher rates of poverty make them more likely to suffer the underlying conditions that make Covid-19 more deadly.People are also more at risk if they cannot work from home. Anthony Skelton, a philosophy professor at the University of Western Ontario, makes a case for sending those in work-at-home professions to the back of the line.” To the extent that racial minorities might live and/or work in conditions that make them less able to avoid coming into contact with infected individuals, the case for giving them priority over people who can work from their home office seems strong,” Skelton said.All of these proposals spring from prioritizing people according to risk, but might in practice look like the kind of redistributionist social-justice crusading that provokes controversy, particularly in the U.S.Rationing could also be affected by where the vaccine was tested. In the case of AIDS, experimental treatments were assessed in Africa, where testing was cheaper, but the treatments then went to developed countries. Severely affected African countries had to pay prohibitive prices as the disease took hold.Africa could become a Covid-19 test site if regulators do not permit human challenge tests elsewhere.  If large-scale testing does happen there, justice will demand that early supplies of the vaccine are made available to Africans, even at the expense of people in the researchers’ home country.How to Roll It Out?Vaccinations work best when everyone receives them, since germs that can’t infect people tend to wither away.But all vaccines come with risks. That creates a “free-rider” problem. The best option from a self-interested point of view is that everybody else has the shot (eliminating your personal risk of catching Covid-19) – but that you don’t (avoiding any personal risk of side-effects). Taxes have the same problem. Taxes are compulsory. Does that mean vaccination should be compulsory, too?The public-health case for compulsion is strong. But libertarians have a problem with forcing a potentially harmful vaccine on someone without the “informed consent” that’s hard to procure in societies skeptical of experts and low on social trust.How can the vaccine reach a critical mass without compulsion? Caplan suggests leaving compulsion to private entities. An employer might demand vaccination as a condition of reporting for work. A university might impose the same requirement on faculty and students. A vaccine might be dangled as a golden ticket to return to theaters, cinemas, night clubs or sports events. Governments or foundations could even pay people to receive a shot.By this thinking, those who assert their right not to be vaccinated would be free to work from home and home-school. They would be voluntarily narrowing their own freedom of movement and assembly.Yet societies would pay a price. The virus has divided humans in countless ways already. If many citizens opt to stay unvaccinated, the virus and the messy ethics of compelling vaccination will have helped to create another permanent division. This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.John Authers is a senior editor for markets. Before Bloomberg, he spent 29 years with the Financial Times, where he was head of the Lex Column and chief markets commentator. He is the author of “The Fearful Rise of Markets” and other books.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Coronavirus update: Fauci, CDC face Congress as US coronavirus cases spiral higher
    Yahoo Finance

    Coronavirus update: Fauci, CDC face Congress as US coronavirus cases spiral higher

    The U.S.’s troubled response to the coronavirus pandemic was on display Friday, as the Trump Administration’s top health officials testified before Congress, warning that the virus’ spread would “likely continue for some time.”

  • Here's How to Build the Safest But Most Promising Coronavirus Portfolio
    Motley Fool

    Here's How to Build the Safest But Most Promising Coronavirus Portfolio

    Some are true believers in the power of sophisticated mRNA vaccines, some go for exotic viral vectors, and some are tied to the time-tested cocktail of attenuated viral particles. Whatever approach you prefer, it's clear there's likely more than one way to make a coronavirus vaccine.

  • Large U.S. COVID-19 vaccine trials will exclude pregnant women for now
    Reuters

    Large U.S. COVID-19 vaccine trials will exclude pregnant women for now

    The first two COVID-19 vaccines to enter large-scale U.S. trials will not be tested in pregnant women this year, raising questions about how this vulnerable population will be protected from the coronavirus, researchers told Reuters. Moderna and Pfizer, which has partnered with Germany’s BioNTech, this week separately launched clinical trials that use a new and unproven gene-based technology. Drugmakers say they first need to make sure the vaccines are safe and effective more generally.

  • How Bill Gates would treat COVID-19 if he were President of the United States
    Yahoo Finance Video

    How Bill Gates would treat COVID-19 if he were President of the United States

    Microsoft Co-Founder Bill Gates joins 'Influencers with Andy Serwer' to discuss the U.S. federal government's pandemic response and how it can improve.

  • Johnson & Johnson's Coronavirus Vaccine Candidate Efficacious in Pre-Clinical Studies; Human Testing Has Begun
    Motley Fool

    Johnson & Johnson's Coronavirus Vaccine Candidate Efficacious in Pre-Clinical Studies; Human Testing Has Begun

    Johnson & Johnson (NYSE: JNJ) has gained some ground in the coronavirus vaccine race. On Thursday, the pharmaceutical and consumer goods company announced that in pre-clinical studies, its Ad26.COV2-S vaccine candidate had demonstrated effectiveness in protecting on non-human primates from infection with SARS-CoV-2. In contrast to other coronavirus vaccine candidates -- such as the one many observers view as the most promising, Moderna's mRNA-1273 -- Johnson & Johnson's produced its response with a single dose.

  • Coronavirus update: Sun Belt surge fans recovery fears; Trump ally Herman Cain dies
    Yahoo Finance

    Coronavirus update: Sun Belt surge fans recovery fears; Trump ally Herman Cain dies

    Grim jobless and economic growth data on Thursday underscored how badly the coronavirus pandemic has damaged the world’s largest economy, as still rising COVID-19 diagnoses amplify concerns for the recovery.

  • Johnson & Johnson starts human study of COVID-19 vaccine after promising monkey data
    Reuters

    Johnson & Johnson starts human study of COVID-19 vaccine after promising monkey data

    When exposed to the virus, six out of six animals who got the vaccine candidate were completely protected from lung disease and five out of six were protected from infection as measured by the presence of virus in nasal swabs, according to the study published in the journal Nature. "This gives us confidence that we can test a single-shot vaccine in this epidemic and learn whether it has a protective effect in humans," Dr. Paul Stoffels, J&J's chief scientific officer, told Reuters in a telephone interview. The drugmaker said it had started early-stage human trials in the United States and Belgium and would test its vaccine candidate in more than 1,000 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older.

  • Influencers with Andy Serwer: Bill Gates
    Yahoo Finance Video

    Influencers with Andy Serwer: Bill Gates

    In this episode of Influencers, Microsoft Co-Founder Bill Gates joins Andy Serwer to discuss his efforts to stop the spread of COVID-19.

  • Bill Gates: We should be able 'to manufacture a lot of vaccines in 2021'
    Yahoo Finance Video

    Bill Gates: We should be able 'to manufacture a lot of vaccines in 2021'

    Microsoft Co-Founder Bill Gates joins 'Influencers with Andy Serwer' to discuss his efforts to stop the spread of COVID-19.

  • J&J starts human safety trial for its COVID-19 vaccine candidate
    Reuters

    J&J starts human safety trial for its COVID-19 vaccine candidate

    When exposed to the virus, six out of six animals who got the vaccine candidate were completely protected from lung disease and five out of six were protected from infection as measured by the presence of virus in nasal swabs, according to the study published in the journal Nature. "This gives us confidence that we can test a single-shot vaccine in this epidemic and learn whether it has a protective effect in humans," Dr. Paul Stoffels, J&J's chief scientific officer, told Reuters in a telephone interview. The drugmaker said it had started early-stage human trials in the United States and Belgium and would test its vaccine candidate in over 1,000 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older.

  • J&J starts human study of COVID-19 vaccine after promising monkey data
    Reuters

    J&J starts human study of COVID-19 vaccine after promising monkey data

    When exposed to the virus, six out of six animals who got the vaccine candidate were completely protected from lung disease and five out of six were protected from infection as measured by the presence of virus in nasal swabs, according to the study published in the journal Nature. "This gives us confidence that we can test a single-shot vaccine in this epidemic and learn whether it has a protective effect in humans," Dr. Paul Stoffels, J&J's chief scientific officer, told Reuters in a telephone interview. The drugmaker said it had started early-stage human trials in the United States and Belgium and would test its vaccine candidate in more than 1,000 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older.

  • 3 Safe and Cheap Dividend Stocks to Buy
    Motley Fool

    3 Safe and Cheap Dividend Stocks to Buy

    Johnson & Johnson (NYSE: JNJ) has always been regarded as the blue-chip dividend stock in the healthcare sector. With a market cap of about $390 billion, J&J is easily the largest healthcare company in the world, something that can certainly indicate a safe investment. The company offers a reliable 2.7% dividend, and although that's far from the highest yield you can find in the healthcare sector, J&J's stock price has made it through some ups and downs -- the stock price is now about where it was at the beginning of the year.

  • Coronavirus update: Pfizer starts Phase 3 trial as Fauci voices optimism on vaccine timeline
    Yahoo Finance

    Coronavirus update: Pfizer starts Phase 3 trial as Fauci voices optimism on vaccine timeline

    The global search for a coronavirus vaccine appears to be taking flight, with a number of drug companies making headway on a possible treatment.

  • TSMC Pares Gains After $72 Billion Surge to Start the Week
    Bloomberg

    TSMC Pares Gains After $72 Billion Surge to Start the Week

    (Bloomberg) -- Taiwan Semiconductor Manufacturing Co. kept up its record-breaking streak Tuesday, briefly becoming the world’s 10th most valuable corporation before paring gains.Taiwan’s biggest stock was up around 1.2% in Taipei, after rising as much as 9.9% and going beyond $410 billion in value, leapfrogging U.S. giants Johnson & Johnson and Visa Inc. in the process. Daily stock moves are capped at 10% in Taiwan’s equity market.It’s difficult to overstate the influence that TSMC wields on Taiwan’s financial markets. Making up almost a third of the local benchmark, it has single-handedly pushed the Taiex past a record that had stood for three decades. Its rally is attracting foreign flows into Taiwanese equities, increasing demand for the local currency. The Taiwan dollar rose 1% Tuesday to the strongest since April 2018.The latest boost to TSMC’s shares came after Intel Corp. warned last week that its 7-nanometer chips are behind schedule and it may outsource their production. The U.S. chipmaker is expected to funnel new business to TSMC, given its global lead in silicon fabrication and track record of making semiconductors for the world’s largest tech corporations.Intel’s struggles are buoying stocks in Asian suppliers of made-to-order chips. Samsung Electronics Co., which is investing heavily in its own foundry business, jumped as much as 5.8% Tuesday, its biggest intraday gain in almost two months. Chinese rival Semiconductor Manufacturing International Corp. climbed 6.6% in Hong Kong.“Samsung Electronics’ position as a foundry partner is expected to rise. Korean investors anticipate that Samsung could produce Intel’s CPU and discrete GPU,” Hana Financial Investment analysts wrote in a note. But “to narrow the gap with TSMC, it is essential for Samsung to expand its Austin fab.”A report on Monday suggested that Intel had placed orders with TSMC for 180,000 units of 6nm chips for 2021. Meanwhile, brokerages including Nomura Holdings Inc. and Credit Suisse Group AG upgraded TSMC to the equivalent of buy.(Updates with share price and analyst comment from first paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Coronavirus update: Moderna starts next vaccine phase as crisis grows for FL, CA
    Yahoo Finance

    Coronavirus update: Moderna starts next vaccine phase as crisis grows for FL, CA

    Florida and California entrenched their status as epicenters of the U.S.’s coronavirus crisis, with both states hammered by rising COVID-19 cases that exceed New York, formerly the domestic leader in infections.

  • Exclusive: EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags - sources
    Reuters

    Exclusive: EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags - sources

    European efforts to secure potential COVID-19 vaccines from Pfizer <PFE.N>, Sanofi <SASY.PA> and Johnson & Johnson <JNJ.N> are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters. The bloc is in talks with at least six vaccine makers to acquire up front doses of potential shots against the novel coronavirus, officials told Reuters earlier in July, in a strategy meant to increase the chances of having COVID-19 vaccines for its population. Despite the urgency to seal deals amid a global race to secure the most promising shots, the EU is struggling to reach swift agreements, said the officials, who are involved in the talks, and declined to be named because the negotiations are confidential.

  • Moderna CEO credits US support for Phase 3 vaccine push, says 'we have to make a profit'
    Yahoo Finance

    Moderna CEO credits US support for Phase 3 vaccine push, says 'we have to make a profit'

    Moderna's CEO told Yahoo Finance on Monday it could not have participated in such a robust trial without the federal government’s support.

  • Is Johnson & Johnson an Underdog in the COVID-19 Vaccine Race?
    Motley Fool

    Is Johnson & Johnson an Underdog in the COVID-19 Vaccine Race?

    You won't have a very difficult time identifying ways that Johnson & Johnson (NYSE: JNJ) is a leader. It's the largest healthcare company in the world with a market cap of close to $400 billion. Johnson & Johnson announced in March that it would invest more than $1 billion to develop a COVID-19 vaccine candidate.

  • Could Fate Therapeutics Be a Millionaire-Maker Stock?
    Motley Fool

    Could Fate Therapeutics Be a Millionaire-Maker Stock?

    Thanks to its powerful platform that enables the efficient mass production of high-impact and high-complexity cellular therapies for cancers and immune disorders, its manufacturing technology licensing revenues alone could be a gold mine. Historically, gathering non-induced stem cells required a donation of human cord blood, making them both expensive to produce and variable from donor to donor, in terms of their cellular properties. Manufacturing iPSCs in small numbers without a human donor isn't new, but the company's innovation is to genetically engineer and culture its iPSCs at scale by generating homogenous cell lines that can be cloned or expanded indefinitely without additional donations.

  • Fauci: Coronavirus Vaccine Likely Not "Widely Available" Until Several Months Into 2021
    Motley Fool

    Fauci: Coronavirus Vaccine Likely Not "Widely Available" Until Several Months Into 2021

    The good doctor is somewhat less optimistic than the leading coronavirus vaccine developers about timing.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more